Description: Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. It develops and commercializes LaminarPace, a spray drying technology that dries liquid biopharmaceuticals, such as vaccines or protein therapeutics into a particle engineered powder product. The company was incorporated in 2017 and is headquartered in Lund, Sweden.
Home Page: ziccum.com
Scheelevägen 22
Lund,
223 63
Sweden
Phone:
Officers
| Name | Title |
|---|---|
| Ms. Ann Gidner | MD & CEO |
| Mr. Xavier Turon | Chief Operating Officer |
| Mr. Fabrice Rose | Scientific Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0808 |
| Price-to-Sales TTM: | 0.2258 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |